PTC Therapeutics (@PTCBio) header
PTC Therapeutics (@PTCBio) profile picture

PTC is a patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for patients with rare disease

United States
Joined May 2009
Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)Photo by PTC Therapeutics (@PTCBio)
PTC's President & CEO Matthew Klein, MD and CFO Pierre Gravier will speak at two upcoming investor conferences to close out the year. Learn more: ow.ly/O5yv5102X14
121
Today we announced our Q3 2026 financial results where we highlighted our continued commercial momentum and raised full-year revenue guidance. Read the press release: ow.ly/CVBZ5102ghh | Webcast: ow.ly/23Qw5102ghi
1
171
PTC will host a web conference to report our third quarter 2026 financial results and provide an update on the company’s business on Thursday, Oct. 29, 2026, at 4:30 p.m. ET. Learn more: ow.ly/hHoP50ZY969
100
Hello, #FabryDisease community. We're honored to introduce ourselves as we advance the investigational gene therapy ST-920 with an FDA submission planned before the end of 2026. Read our letter to the community: ow.ly/XhNx50ZTegw
1
505
PTC will participate in three upcoming investor conferences in September. Learn more: ow.ly/5sSy50ZG4kj
190
#SSIEM2026 is a meaningful moment for the PKU community. At the meeting multiple scientific data presentations spanning research, clinical outcomes & real-world case studies will be featured. ow.ly/cbU150ZEJTG
1
235
PTC Therapeutics was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease – from Sangamo Therapeutics in a competitive bankruptcy auction. Learn more: ow.ly/O0ie50Zz6cz
3
1
3
1,511
PTC Therapeutics welcomes Hege Sollie-Zetlmayer to its Board of Directors. With 30 years experience in biopharma and medical devices, including eight at PTC as CHRO, she brings deep global leadership to advance our mission for patients with rare diseases.
172
Today we announced our Q2 2026 financial results, highlighting strong commercial momentum with accelerating global uptake of our treatment for PKU. Learn more in our press release: ow.ly/Z4Tv50ZuPSH | Webcast: ow.ly/9GWI50ZuPST
1
208
PTC will host a web conference to report our second quarter 2026 financial results and provide an update on the company’s business on Thursday, July 30, 2026, at 4:30 p.m. ET. Learn more: ow.ly/Cr3a50Zojcl
1
169
Every day, the #PKU community faces unseen challenges. This #InternationalPKUDay, PTC is making a #PledgeForPKU: to listen, learn and support everyone this journey. Join us in championing hope, access and a future without limits. ow.ly/QosX50ZhKTo
176
Ahead of International PKU Day, we’re spotlighting mental health in the PKU community. Kevin, Signe & Regina share their journeys with stigma, anxiety & resilience. Learn more about their stories: ow.ly/YqMQ50ZbgLL
158
Our 2025 Corporate Social Responsibility Report highlights a year of focus, execution and measurable progress delivering differentiated medicines for people with rare disorders. See how we're driving impact across access, innovation, people & our planet: ow.ly/gwTR50Z6RRt
118
On #ClinicalTrialsDay, we honor patients, families, and clinical teams advancing rare disease research. This year's #ResearchRising theme reminds us that progress comes from partnership and trust. Learn more: ow.ly/wJiY50Z1Ml5
1
2
170
May is Friedreich’s ataxia (FA) Awareness Month and we're proud to honor the strength of those living with this rare condition. Kailey’s journey reflects the challenges many face, from recognizing symptoms to finding support. Learn more: ow.ly/KkRx50YZAmQ
2
7
444
Some days, the hardest part of living with a rare disorder isn’t what others can see—it’s the uncertainty: navigating genetic testing barriers and painful life changes. During #HDAwarenessMonth, PTC is proud to share stories like April's. Learn more: ow.ly/F1os50YWhRo
3
1
5
211
Today, we announced our Q1 2026 financial results, highlighting record performance and continued momentum across the business—led by the global launch of our treatment for #PKU. See the release: ow.ly/lbyh50YWi0T and webcast recording: ow.ly/5l7u50YWi1B
2
234
PTC will participate in three upcoming investor conferences in May and June. Learn more: ow.ly/sGsN50YVbXo
1
1
136
This #NationalPKUAwarenessMonth, we’re honoring the resilience of the PKU community. Living with PKU is more than a diet—it takes constant planning, advocacy and support. Amanda’s story, alongside her mom Jill, helps make the invisible visible. Learn more: ow.ly/kfKX50YTBSG
2
3
197
On Rare Disease Day, we recognize the millions living with rare conditions. At PTC, we know that progress starts with listening to those impacted. Together, we can make a difference. Learn more: ow.ly/pwXK50YliIh
3
4
411